

COMBINE –

OPEN CALL for clinical data sets

COMBINE is an IMI2 consortium part of the AMR Accelerator, which supports the development of novel medicines to treat or prevent AMR infections. To this end, COMBINE aims to optimize clinical trial design and data analysis, and will perform systematic cross-study analyses of relevant data sets originating from the AMR community, with the goal of improving the success of R&D efforts across the AMR community.

The COMBINE consortium is launching its first **OPEN CALL FOR DATA** to find partners worldwide that are willing to share data from **studies of prevention or treatment of bacterial infections**. The extended analyses we can perform using your data will help the AMR community to learn from the body of available science. **YOU** can help to prevent future failures and increase success rates of future developments by giving COMBINE access to data.

What are WE looking for?

Data from the study of medicines or candidate medicines for prevention or treatment of bacterial infections, e.g. **antibiotics, vaccines, and monoclonal antibodies**.

We are specifically looking for:

- 1.) ESKAPE pathogens
- 2.) *Escherichia coli*, ideally ESBL positive *E. coli*
- 3.) *Clostridioides difficile*

Data from **all relevant trials, both success and failures, are highly relevant** to derive the desired learnings.

www.amr-accelerator.eu

What pathogens are WE interested in?

ESKAPE pathogens, *Escherichia coli* (especially ESBL positive), and *Clostridioides difficile*.

What is in it for you?

- Improve your data management process and get more out of your data.
- Get access to the results of the aggregated analyses before they are made public.

Are YOU interested?

Please send an e-mail to

AMR-data-technical.COMBINE@grit42.com to submit your **Expression of Interest** or ask technical questions; or at **IMI-COMBINE@pei.de** to understand what type of analysis we could perform with your data sets

CLICK HERE FOR MORE INFORMATION



innovative
medicines
initiative



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853967. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.